Efficacy Of Sodium Glucose Transporter Inhibitor (SGLT2I) In Adult Patients With Congenital Heart Disease
The goal of the study is to investigate the feasibility and benefit of novel guideline-directed heart failure therapy drug Empagliflozin (Jardiance) for adult patients with congenital heart disease (ACHD).
- EligibilityCriteria: Inclusion Criteria:  Diagnoses of Congenital Heart Disease Age 18+ ACHD level of structural complexity II or III Recent (<6 months) decrease in systemic Ejection Fraction (confirmed by cardiac Echocardiogram, Computed Tomography or cMRI) to EF < 60% Recent decrease in systemic ejection fraction confirmed by cardiac Echo, CT or MRI by > 5% in the last 6 months or less. Must be able to complete neurocognitive assessments on a handheld computer.  Exclusion Criteria:  Diagnosed with Diabetes Contraindication to Jardiance/Entresto or any heart failure medication (per guideline-directed therapy, 2022). Previous therapy with Jardiance at <4 weeks Glomerular Filtration Rate <20 Pregnancy, breastfeeding, or planning to become pregnant in the coming year History of liver disease - including non-alcoholic fatty liver disease (NAFLD) and cirrhosis History of inborn error(s) of metabolism (including but is not exclusive of Glycogen storage disease type 1) Glucose-galactose malabsorption, familial hyperinsulinism, maple syrup urine disease, Gaucher disease, Tay-Sachs disease, Mucolipidosis IV, Niemann-Pick disease, Type A mitochondrial disease, Metabolic disorders related to glucose metabolism - HealthyVolunteers: No - Gender: All - MinimumAge: 18 Years - StdAgeList: Adult, Older Adult